Immunomodulators for Steroid-Dependent Recurrent Acute Pancreatitis After Immune Checkpoint Inhibitor Therapy: A Case Series

One to 2% of patients undergoing immune checkpoint inhibitor (ICI) therapy develop ICI-induced pancreatitis (ICI-IP). A small subset of these patients develop recurrent pancreatitis, even after discontinuation of ICI therapy. This case series presents 2 patients with recurrent steroid-responsive ICI-IP who were managed with immunomodulators as steroid-sparing agents. Both patients were maintained on immunomodulators for approximately 2 years before discontinuation of the agents, with no further recurrence or complications of pancreatitis. This case series highlights the use of mycophenolate mofetil and azathioprine for the management of recurrent ICI-IP.